DNA Link Inc (127120) - Total Liabilities
Based on the latest financial reports, DNA Link Inc (127120) has total liabilities worth ₩53.95 Billion KRW (≈ $36.56 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DNA Link Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how DNA Link Inc's total liabilities have evolved over time, based on quarterly financial data. See DNA Link Inc (127120) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
DNA Link Inc Competitors by Total Liabilities
The table below lists competitors of DNA Link Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Valeura Energy Inc
TO:VLE
|
Canada | CA$429.55 Million |
|
R&S GROUP HOLDING AG
SW:RSGN
|
Switzerland | CHF262.41 Million |
|
Osisko Development Corp
V:ODV
|
Canada | CA$616.83 Million |
|
Dongfeng Electronic Technology Co Ltd
SHG:600081
|
China | CN¥4.22 Billion |
|
Ads Tec Energy PLC
NASDAQ:ADSE
|
USA | $101.03 Million |
|
engcon AB Cl B
ST:ENGCON-B
|
Sweden | Skr653.00 Million |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥121.73 Million |
|
Lsb Industries Inc
NYSE:LXU
|
USA | $648.41 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down DNA Link Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 127120 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DNA Link Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DNA Link Inc (2011–2025)
The table below shows the annual total liabilities of DNA Link Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩54.44 Billion ≈ $36.90 Million |
+85.46% |
| 2024-12-31 | ₩29.36 Billion ≈ $19.89 Million |
+135.23% |
| 2023-12-31 | ₩12.48 Billion ≈ $8.46 Million |
-20.09% |
| 2022-12-31 | ₩15.62 Billion ≈ $10.58 Million |
+89.40% |
| 2021-12-31 | ₩8.25 Billion ≈ $5.59 Million |
-40.42% |
| 2020-12-31 | ₩13.84 Billion ≈ $9.38 Million |
-14.77% |
| 2019-12-31 | ₩16.24 Billion ≈ $11.00 Million |
+5.02% |
| 2018-12-31 | ₩15.46 Billion ≈ $10.48 Million |
+996.65% |
| 2017-12-31 | ₩1.41 Billion ≈ $955.48K |
-94.14% |
| 2016-12-31 | ₩24.04 Billion ≈ $16.29 Million |
+11.69% |
| 2015-12-31 | ₩21.53 Billion ≈ $14.59 Million |
+68.92% |
| 2014-12-31 | ₩12.74 Billion ≈ $8.64 Million |
+3.34% |
| 2012-12-31 | ₩12.33 Billion ≈ $8.36 Million |
+37.43% |
| 2011-12-31 | ₩8.97 Billion ≈ $6.08 Million |
-- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more